References
- Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. doi:10.1093/ecco-jcc/jjw168.
- Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi:10.1093/ecco-jcc/jjx008.
- Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:10.1093/ecco-jcc/jjx009.
- Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scand J Gastroenterol. 2015;50(3):312–320.
- Clarke B, Yates M, Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology (Oxford). 2021;60(Suppl. 2):ii24–ii30. doi:10.1093/rheumatology/keaa895.
- Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655. doi:10.1183/13993003.00655-2019.
- World Health O. WHO global lists of high burden countries for tuberculosis (TB). In TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: background document. Geneva: World Health Organization; 2021.
- Rao M, Ippolito G, Mfinanga S, et al. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. Int J Infect Dis. 2019;80s:S58–S61. doi:10.1016/j.ijid.2019.02.035.
- Hasan T, Au E, Chen S, et al. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open. 2018;8(9):e022445. doi:10.1136/bmjopen-2018-022445.
- Fehily SR, Al-Ani AH, Abdelmalak J, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56(1):6–27. doi:10.1111/apt.16952.
- Hakimian S, Popov Y, Rupawala AH, et al. The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation. Biologics. 2018;12:61–67. doi:10.2147/BTT.S150958.
- Lovatt J, Gascoyne-Binzi D, Hussey T, et al. Screening for TB in hospitalised patients with inflammatory bowel disease before anti-TNF therapy: is QuantiFERON(®) gold testing useful? J Clin Med. 2021;10(9):1816. doi:10.3390/jcm10091816.
- Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl. 2014;91:32–40. doi:10.3899/jrheum.140100.
- Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl. 3):s1–s106. doi:10.1136/gutjnl-2019-318484.
- Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639. doi:10.1002/acr.21641.
- Uzorka JW, Wallinga J, Kroft LJM, et al. Radiological signs of latent tuberculosis on chest radiography: a systematic review and meta-analysis. Open Forum Infect Dis. 2019;6(7). doi:10.1093/ofid/ofz313.
- Pepper T, Joseph P, Mwenya C, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis. 2008;12(4):397–403.
- Marciniuk DD, McNab BD, Martin WT, et al. Detection of pulmonary tuberculosis in patients with a normal chest radiograph. Chest. 1999;115(2):445–452. doi:10.1378/chest.115.2.445.
- Institut Ss. Tuberculosis 2019 - 2020 en.ssi.dkn.d; 2022. [updated 4. February]. Available from: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/tuberculosis-2019–-2020.
- Yamasue M, Komiya K, Usagawa Y, et al. Factors associated with false negative interferon-γ release assay results in patients with tuberculosis: a systematic review with meta-analysis. Sci Rep. 2020;10(1):1607. doi:10.1038/s41598-020-58459-9.
- Organization WH. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: background document; 2021.